Hidradenitis Suppurativa

The Lancet data is the primary publication of bimekizumab results from BE HEARD I and BE HEARD II.

VELA is the first phase 3 hidradenitis suppurativa trial to evaluate HiSCR75 as the primary end point.

Researchers have developed a clinical decision support model using machine learning to assist health care providers in predicting diagnoses of hidradenitis suppurativa.

Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.

Researchers conducted a population-based study examining a sample of patients with HS during hospital admissions.

The European approval was based on data from the Phase III BE HEARD I and BE HEARD II trials.

A study demonstrated the favorable efficacy and safety profiles of secukinumab in patients with severe HS for up to 52 weeks.

MoonLake’s sonelokimab is being evaluated for hidradenitis suppurativa, psoriasis, and psoriatic arthritis.

The submission stems from promising results from the phase 3 BE HEARD I and BE HEARD II trials.

Povorcitinib is being evaluated for non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria.

Researchers found that patients who initiated gender-affirming hormone therapy with testosterone were more likely to experience a worsening of their HS symptoms.

If approved, bimekizumab will be the first IL-17A and IL-17F inhibitor approved in Europe for hidradenitis suppurativa.

Presented at the American Academy of Dermatology Annual Meeting, the poster was the winner of the second place poster award.

Maria Aleshin, MD, FAAD, presented surgical procedures for HS that can be performed in the office.

The phase 3 studies, BE HEARD I and BE HEARD II, showed significant improvements in skin pain over the 48-week period.

Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa.

How can you improve excision care for your patients with hidradenitis suppurativa? Ashley Nicole Elsensohn, MD, MPH, FAAD, shared clinical pearls at the AAD Annual Meeting.

Findings regarding an association between HS severity and dietary elements such as vitamin D, B12 supplementation, and more, are inconclusive.

Researchers from the University of Michigan and Almirall found that the profibrotic fibroblast response in HS can be modulated through inhibition of the Hippo pathway.

IV antibiotics should play a complementary role in the management of HS as new immunomodulator therapies are developed, researchers concluded.

To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists.

Higher response rates were observed in patients treated with lutikizumab. The drug will now advance to phase 3 clinical trials.

Results of this study may also be indicative of oral orismilast's ability to contribute to meaningful clinical improvements, investigators noted.

This CME credit opportunity delves into the pathogenesis and management of hidradenitis suppurativa.

Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics, spoke with Dermatology Times to discuss these trial results.

More than 80% of patients did not experience an increase in number of draining tunnels associated with HS by week 52.

After maintenance treatment with sonelokimab dosed every 4 weeks, 57% of patients achieved HiSCR75 at week 24.

UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.

The addition of an HS dataset adds approximately 26,000 new patient records.